CCEPR: A Promising Approach to combat cervical carcinoma (G105682749)
CCEPR: A Promising Approach to combat cervical carcinoma
Cervical carcinoma is the most common type of cervical cancer, and it is a leading cause of cancer death in women worldwide. Despite advances in treatment, the survival rate for advanced cervical cancer remains poor, highlighting the need for new and effective therapies. One promising approach to combat cervical carcinoma is the use of small non-coding RNAs (ncRNAs), such as CCEPR (cervical carcinoma expressed PCNA regulatory lncRNA). In this article, we will explore the potential of CCEPR as a drug target or biomarker for cervical carcinoma.
What is CCEPR?
CCEPR is a non-coding RNA that is expressed in the cervical tissue of women with cervical carcinoma. It is characterized by the presence of a unique stem-loop structure and a conserved core region that is enriched forG-Crichness. CCEPR has been shown to play a role in the regulation of cell proliferation and apoptosis, which are important processes in the development and progression of cervical carcinoma.
Expression of CCEPR
Studies have shown that CCEPR is highly expressed in the cervical tissue of women with cervical carcinoma, and it is associated with poor prognosis in these patients. CCEPR has been shown to be involved in the regulation of cell growth and apoptosis, which are important processes in the development and progression of cervical carcinoma. For example, a study by Xu et al. found that CCEPR was involved in the regulation of cell apoptosis in cervical cancer cells.
Drug Targeting
Despite the promising results of CCEPR's involvement in cervical carcinoma, drug targeting of this RNA is still a challenging task. However, recent studies have identified potential drug targets for CCEPR. For example, a study by Zhao et al. identified a potential drug target for CCEPR by using a bioinformatics screen. The results of this study identified a potential drug target for CCEPR, which is involved in the regulation of cell apoptosis.
Biomarker
In addition to its potential as a drug target, CCEPR has also been shown to be a potential biomarker for cervical carcinoma. Studies have shown that CCEPR is downregulated in cervical cancer cells, and it has been used as a potential biomarker for cervical cancer. For example, a study by Wang et al. found that CCEPR was downregulated in cervical cancer cells and was associated with poor prognosis.
Conclusion
In conclusion, CCEPR is a promising RNA that has been shown to be involved in the regulation of cell proliferation and apoptosis in cervical carcinoma. Its potential as a drug target or biomarker makes it an attractive target for further research. Further studies are needed to fully understand the role of CCEPR in cervical carcinoma and to develop effective therapies based on this RNA.
Protein Name: Cervical Carcinoma Expressed PCNA Regulatory LncRNA
The "CCEPR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCEPR comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CCER1 | CCER2 | CCHCR1 | CCIN | CCK | CCK receptor | CCKAR | CCKBR | CCL1 | CCL11 | CCL13 | CCL14 | CCL15 | CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2
